indication

Delusions

Competitive landscape

as of 2026-07-01
Competitive set
4
4 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
39 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 43 trials
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugRecruiting
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 42 trials
OwnerAstraZeneca
Protection—
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
—1 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042

Market size

prevalence as a range, not a number